

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 5, 2007.

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

AMENDMENT UNDER 37 C.F.R.  
§1.825(a) THROUGH (c)  
Examining Group 1632  
Patent Application  
Docket No. USF-182XC1  
Serial No. 10/655,873

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Marcia Stephens Noble  
Art Unit : 1632  
Applicants : Shyam S. Mohapatra, Mukesh Kumar  
Serial No. : 10/655,873  
Filed : September 5, 2003  
Confirm. No. : 6872  
For : Genetic Adjuvants for Immunotherapy

MS SEQUENCE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.825(a) THROUGH (c)

Sir:

An Amendment under 37 C.F.R. §1.111 was transmitted to the Patent Office on June 26, 2007. It is respectfully requested that the subject application be amended as follows, in order to comply with the requirements of 37 C.F.R. §§1.821-1.825: